Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXI-003 in HPV-related Oropharyngeal Cancers
NCT05582590Phase 1Not yet recruiting
- Sponsor
- NexImmune, Inc.
- Start
- Mar 2025
- Primary completion
- Jul 2026
- Modality
- Native Immune Cells
01
Overview
Phase 1, open-label trial of NEXI-003 in Human papillomavirus-related oropharyngeal cancer (HPV-OPC) (5 arms), sponsored by NexImmune, Inc. Primary endpoints: Adverse Events at 12 months, Dose-Limiting Toxicities at 28 days and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
NEXI-003
03
Conditions
Human papillomavirus-related oropharyngeal cancer (HPV-OPC)
Beyond the preview
Go deeper on NCT05582590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582590.